Steady-state pharmacokinetics of lithium in healthy volunteers receiving concomitant meloxicam

摘要: Aims This open, controlled study investigated the effect of concomitant 15 mg oral meloxicam on pharmacokinetics lithium in healthy male volunteers. Methods On days 1–14 was coadministered with to 16 volunteers; 10–14 administered individualized dosage regimes achieve stable plasma concentrations lower therapeutic range 0.3–0.7 mmol l−1. A 12 h steady-state concentration profile for obtained at day 14, after which withdrawn. The dose remained unchanged from 15 22, time a second determined. Results Lithium and were well tolerated throughout all volunteers completed study. predose (Cpre,ss) area under curve (AUCss) values both increased by 21% (paired t-test P = 0.0002; 90% confidence intervals test/reference ratios: 113–130% 115–128%, respectively) when compared alone. geometric mean Cpre,ss 0.65 mmol l−1 0.54 mmol l−1 Cmax,ss 16% coadministration meloxicam, 0.97 mmol l−1 1.12 mmol l−1. total clearance administration (82.5% value alone). Conclusions Meloxicam (15 mg) moderately volunteers, but magnitude thought be low clinical relevance. Nevertheless, should closely monitored patients receiving therapy.